Carnegie Mellon University recently licensed Coya Therapeutics, a clinical-stage biotechnology company, for a proprietary platform of bioengineered exosomes used in drug delivery.
Exosomes are extracellular vesicles that can be released from cells and can contain proteins, lipids, metabolites, and nucleic acids.
Researchers are working to harness the exosome as a drug delivery vehicle, but not all attempts have been successful. Coya Therapeutics plans to develop exosome-polymer hybrids (EPHs) to allow exosomes to be housed in specific proteins.
Under the agreement, Coya has opted for exclusive worldwide rights to research, develop, manufacture and market EPHs developed by CMU’s interdisciplinary team of chemists and engineers.
“This collaboration with Carnegie Mellon University further strengthens Coya’s thought leadership in the global exosome therapeutic area, adding exciting new technologies to our unique Treg-derived exosome platform,” said Howard Berman, CEO of Coya. Therapeutics. “Nano-engineering exosomes with such manufacturing efficiency to produce EPHs that can be customized for any surface protein, delivering growth factors or drugs, while enhancing cellular uptake and bioactivity is the future of targeted therapies.”
CMU researchers have created a method that designs exosomes using a DNA-cholesterol tether. The synthetic single-stranded DNA on the tether binds to a complementary strand of DNA bound to a bioactive agent.